Massive Bio Inroduces Global Platform Launches to Enhance Patient Access to Clinical Trials
Massive Bio, an industry leader in AI-powered clinical trial enrollment, has introduced Patient Connect, an innovative portal designed to...
Exelixis Announces Phase 3 CABINET Study Results Unveiled at ESMO 2024
The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this...
SubjectWell Acquires Trial24
SubjectWell bolsters its global patient recruitment capabilities by acquiring Trials24. The merger combines SubjectWell’s accuracy, diverse patient pool, and...
DeepCure: Unveiling the Potential of BD2 Inhibitor DC-9476 in Macrophage Activation Syndrome
DeepCure, a company employing AI for drug discovery, will present preclinical data on their BRD4 Inhibitor, DC-9476, at the...
Ferrer Headway with First Phase II Participant
Ferrer, a B Corp-certified pharmaceutical company, has initiated a Phase II clinical trial, PROSPER, to assess the safety and...
CD137 Antibodies: A Promising Cancer Immunotherapy Target
CD137 (4-1BB) is a promising target for cancer immunotherapy. Its ability to stimulate T cells and enhance tumor cell...
Introducing NTx Services: Revolutionizing Next-Gen mRNA Research
Nature’s Toolbox (NTx) has launched NTx Services, providing high-integrity, complex mRNA production using its innovative NTxscribe® RNA manufacturing system....
Tivic Health Study Ready for Enrollment With Non-Invasive Vagus Nerve Stimulation Technology
Tivic Health has received approval for the next phase of clinical research on its non-invasive cervical vagus nerve stimulation...
Azitra Gets Fast Track for EGFRi-Associated Skin Toxicity
Azitra, a biopharmaceutical company specializing in precision dermatology, has announced the FDA’s Fast Track Designation for ATR-04, a novel...
Fasenra: A Breakthrough in Treating Eosinophilic Granulomatosis with Polyangiitis
AstraZeneca‘s FASENRA (benralizumab) has received FDA approval for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune...